Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Genfit (OTC: GNFTF).

Full DD Report for GNFTF

You must become a subscriber to view this report.


Recent News from (OTC: GNFTF)

Genfit And GenKyoTex: The Clinical Promise In PBC
Nothing can dim the light that shines from within - Maya Angelou Introduction Genfit ( GNFTF ) and GenKyoTex (GKTX.PA) are both French clinical-stage biopharmaceutical companies with unique and different therapeutic approaches to primary biliary cholangitis ((PBC)). I previously affirm...
Source: SeekingAlpha
Date: December, 07 2018 16:40
Genfit Announces Positive Data For Chronic Liver Disease Using Its NASH Drug
Recently, Genfit ( OTCPK:GNFTF ) announced that it had received positive results treating patients with primary biliary cholangitis (PBC). These positive results were obtained using the company's NASH drug elafibranor. Positive results from the study were obtained after patients were tre...
Source: SeekingAlpha
Date: December, 07 2018 09:15
Biotech Analysis Central Pharma News: Pfizer's Setback, Genfit's Advance, Sage's Postponement
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Pfizer Suffers Setback With Partner Merck KGaA On PD-L1 Drug Bavencio News: Recently, Pfizer ( PFE ) and Merck KGaA ( MKKGY ) announced that they...
Source: SeekingAlpha
Date: November, 20 2018 17:50
NGM Biopharmaceuticals And NASH: Making Progress
Any man or institution that tries to rob me of my dignity will lose - Nelson Mandela Introduction The once dormant clinical research and development of therapies for the non-viral liver disease, NASH, is now characterized by intense competition with over 30 innovative drug candidate...
Source: SeekingAlpha
Date: November, 19 2018 15:29
GENFIT SA announces plans to conduct a registered public offering of its ordinary shares in the United States
GENFIT SA ( OTCPK:GNFTF ) plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares in the United States. More news on: Genfit, Read more ...
Source: SeekingAlpha
Date: November, 19 2018 07:34
5 European Biotech Bargains
Introduction European biotech stocks have a lower valuation in general than American biotechs. It is an observation that many sector followers have already made. In my opinion the cause can be found in the overall ecosystem for biotech. In the United States there is more appetite for this pa...
Source: SeekingAlpha
Date: November, 07 2018 12:08
Expected Value Investing:  Analyzing Genfit's Huge Potential
In this article, I'd like to continue my recent focus on some of the major players in the NASH drug development race. Genfit (OTCPK: GNFTF ), a France-based biotech, is one of the firms farthest along in the development process - it is currently in process of conducting a Phase 3 trial to eva...
Source: SeekingAlpha
Date: October, 19 2018 08:00
Genfit And PBC: Is Elafibranor A Contender?
Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Investment Thesis Genfit (GNFTF) is a small cap ($686M) French clinical stage biopharmaceutical company focused on the early diagnosis and preventive treatment of cardiometabolic disorders of high un...
Source: SeekingAlpha
Date: October, 10 2018 18:21
Expected Value Investing:  The Case Against Galmed
In June, Galmed (NASDAQ: GLMD ) announced data from its Phase 2b trial evaluating its lead drug candidate Aramchol's ability to reduce liver fat in patients with NASH fibrosis . Though the drug failed its primary endpoint, it did demonstrate a moderate ability to reduce liver fat, improve ...
Source: SeekingAlpha
Date: October, 05 2018 12:20
NASH players under pressure following Liver Meeting abstract drop
Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals...
Source: SeekingAlpha
Date: October, 02 2018 12:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-11N/A24.105N/AN/A0
2018-12-1024.10524.10524.10524.105175
2018-12-0725.0024.5225.0024.521,525
2018-12-0623.8124.4824.4823.811,304
2018-12-05N/A22.62N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10175175100.0000Short
2018-12-07251,5251.6393Cover
2018-12-061,0221,30478.3742Short
2018-12-033030100.0000Short
2018-11-309622143.4389Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GNFTF.


About Genfit (OTC: GNFTF)

Logo for Genfit (OTC: GNFTF)

Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.

 

Contact Information

 

 

Current Share Structure

     



    Daily Technical Chart for (OTC: GNFTF)

    Daily Technical Chart for (OTC: GNFTF)


    Stay tuned for daily updates and more on (OTC: GNFTF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: GNFTF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GNFTF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GNFTF and does not buy, sell, or trade any shares of GNFTF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/